(Q54481541)

English

Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Escherichia coli

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Marcel Maier

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Timothy J Seabrook

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Cynthia A Lemere

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

23

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

44

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

5149-5159

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Strategies for disease modification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Nerve inflammation halts trial for Alzheimer's drug.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Set back to Alzheimer vaccine studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cancer vaccines entering Phase III clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids--a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin and related enterotoxins as potent immune modulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Species-specific immune response to immunization with human versus rodent A beta peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.06.018

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54481541&oldid=1775334842"